Liposomes encapsulating adenosine
AssigneesNew York University, Regenosine, Inc.
InventorSiddhesh R. Angle
Life of this patent
Estimating the term…
Abstract
Provided are liposomes that encapsulate adenosine. The liposomes may be formed from sphingomyelin or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol (DMPG) or a combination of sphingomyelin, DMPG, and DMPC. The liposomes encapsulating adenosine may be used to induce cartilage regeneration, treat osteoarthritis, alleviate joint pain, and/or slow, arrest, and/or reverse progressive structural tissue damage associated with osteoarthritis or treat osteoarthritis, rheumatoid arthritis, acute gouty arthritis, and/or synovitis. The liposomes may release adenosine for up to two weeks.
Claims20
An injectable formulation comprising saline and unilamellar liposomes, wherein the liposome lamella comprise 70 to 100% by mass sphingomyelin and when there is less than 100% by mass sphingomyelin the remainder is 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or 1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol (DMPG) or DMPC and DMPG together, wherein the liposomes
- (a) have a diameter of 250 nm or less;
- (b) encapsulate adenosine in the aqueous compartment of the liposome;
- and
- (c) the liposomes have an encapsulation efficiency of at least 4%.
Dependencies are inferred from the claim text.